Form 4: CRISPR Therapeutics Director Receives Option Grant

Director Sandesh Mahatme was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard compensation.

Summary

• Director Sandesh Mahatme received a grant of 13,000 stock options for CRISPR Therapeutics AG common shares.
• The options have an exercise price of $51.84 per share.
• The grant date for these options is June 5, 2026.
• The options are set to expire on June 5, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common shares relative to the $51.84 exercise price.

Future Outlook

The options vest in 12 equal monthly installments, with the final vesting occurring by the 2027 Annual Meeting or the one-year anniversary of the grant.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain high-level expertise for oversight of complex R&D pipelines.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard corporate governance practices for mid-cap biotech firms.
• The use of monthly vesting over one year is a common retention mechanism for board members.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Vesting of the first installment of options on June 30, 2026.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Form 4, Insider Trading, Stock Options, Biotech